Table 3.
Antiplatelet and anticoagulant therapy and anti-MPN therapy
| All patients | PV | ET | PMF | Post-PV-MF | Post-ET-MF | MPN-U | p value# | |
|---|---|---|---|---|---|---|---|---|
| Antiplatelet drugs | ||||||||
| ASSa; n (%) | 248 (57.4) n = 432 |
92 (67.2) n = 137 |
83 (61.5) n = 135 |
45 (42.9) n = 105 |
11 (61.1) n = 18 |
10 (52.6) n = 19 |
7 (38.9) n = 18 |
0.0026 |
| P2Y12 antagonista; n (%) | 27 (6.4) n = 425 |
9 (6.7) n = 134 |
13 (9.7) n = 134 |
4 (3.9) n = 104 |
0 (0) n = 17 |
0 (0) n = 18 |
1 (5.6) n = 18 |
0.4064 |
| Anticoagulants | ||||||||
| VKA; n (%) | 43 (9.8) n = 437 |
14 (10.1) n = 138 |
13 (9.5) n = 137 |
6 (5.6) n = 107 |
4 (21.1) n = 19 |
3 (16.7) n = 18 |
3 (16.7) n = 18 |
0.1511 |
| Rivaroxaban; n (%) | 8 (1.8) n = 437 |
3 (2.2) n = 138 |
1 (0.7) n = 137 |
4 (3.7) n = 107 |
0 (0) n = 19 |
0 (0) n = 18 |
0 (0) n = 18 |
0.6151 |
| Heparin; n (%) | 16 (3.8) n = 417 |
4 (3.1) n = 131 |
4 (3.1) n = 131 |
5 (4.9) n = 103 |
2 (11.1) n = 18 |
1 (5.9) n = 17 |
0 (0) n = 17 |
0.4345 |
| Anti-MPN therapyb | ||||||||
| Watch wait; n (%) | 226c
(51.7) n = 437 |
79 (57.7) n = 137 |
72 (52.9) n = 136 |
49 (46.2) n = 106 |
7 (33.3) n = 21 |
6 (31.6) n = 19 |
13 (72.2) n = 18 |
0.0321 |
| Hydroxyurea; n (%) | 215 (49.2) n = 437 |
82 (59.9) n = 137 |
67 (49.3) n = 136 |
38 (35.9) n = 106 |
10 (47.6) n = 21 |
9 (47.4) n = 19 |
9 (50) n = 18 |
0.0151 |
| Anagrelide; n (%) | 66 (15.1) n = 437 |
15 (11.0) n = 137 |
32 (23.5) n = 136 |
11 (10.4) n = 106 |
3 (14.3) n = 21 |
4 (21.1) n = 19 |
1 (5.6) n = 18 |
0.0255 |
| Ruxolitinib; n (%) | 87 (19.9) n = 437 |
15 (11.0) n = 137 |
5 (3.7) n = 136 |
43 (40.6) n = 106 |
11 (52.4) n = 21 |
12 (63.2) n = 19 |
1 (5.6) n = 18 |
<0.0001 |
| IMIDe; n (%) | 21 (4.8) n = 437 |
2 (1.5) n = 137 |
0 (0) n = 136 |
15 (14.2) n = 106 |
2 (9.5) n = 21 |
1 (5.3) n = 19 |
1 (5.6) n = 18 |
<0.0001 |
| IFNα; n (%) | 40 (9.2) n = 437 |
12 (8.8) n = 137 |
15 (11.0) n = 136 |
9 (8.5) n = 106 |
2 (9.5) n = 21 |
1 (5.3) n = 19 |
1 (5.6) n = 18 |
0.9681 |
| SCT; n (%) | 20 (4.6) n = 439 |
3 (2.2) n = 139 |
0 (0) n = 134 |
12 (11.1) n = 108 |
2 (9.5) n = 21 |
2 (10.5) n = 19 |
1 (5.6) n = 18 |
<0.0001 |
VKA vitamin K antagonist, WatchWait watchful waiting, SCT stem cell transplantation
#In Fisher’s exact test
aDouble platelet inhibition in n = 20 patients (4.72 %)
bLife-time therapy
c n = 114 patients (26 %) solely had watchful waiting strategy